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Aims Heart failure (HF) is an important clinical problem. Expert consensus has defined HF as a primary care-sensitive condition
for which the risk of unplanned admissions may be reduced by high quality primary care, but there is little supporting
evidence. We analysed time trends in HF admission rates in England and risk and protective factors for admission.
Methods
and results
We used Hospital Episodes Statistics to produce indirectly standardized HF admission counts by general practice for
2004–2011. Clustered negative binomial regression analysis produced admission risk ratios and assessed the significance
of potential explanatory covariates. These included population factors (deprivation; HF, coronary heart disease, and
smoking prevalence), primary care resourcing [access; general practitioner (GP) supply], and primary care quality
(‘Quality and Outcomes Framework’ indicator.) There were 327 756 HF admissions of patients registered with 8405
practices over the study period. There was a significant reduction in admissions over time, from 6.96/100 000 in 2004
to 5.60/100 000 in 2010 (P, 0.001). Deprivation and HF prevalence were risk factors for admission. GP supply and
access protected against admission. However, these effects were small and did not explain the large and highly significant
annual trend in falling admission rates.
Conclusions The observed fall in admissions over time cannot be explained by the primary care covariates we included. This analysis
suggests that the potential for further significant reduction in emergency HF admissions by improving clinical quality of
primary care (as currently measured) may be limited. Further work is required to identify the reasons for the reduction
in admissions.
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Introduction
Heart failure (HF) is a complex clinical syndrome of symptoms and
signs caused by structural or functional impairment of the heart,
resulting in impaired pumping efficiency. It affects about 900 000
people in the UK,1 and. 23 million worldwide,2 reduces quality of
life, and carries a poor prognosis for patients.3 High numbers of
patients require hospital admission each year.4 Furthermore, treat-
ment is costly to society, consuming  2% of healthcare budgets
annually.5 HF is the only major cardiovascular disease which has
been increasing in prevalence over time.6
HF is considered to be a primary care-sensitive condition (PCSC).
PCSCs, also known as ambulatory care-sensitive conditions, are dis-
eases where, according to expert consensus, improving the quality of
primary care may reduce the risk of emergency admissions. PCSC
lists have been produced by the US and UK governments and by
the Organisation for Economic Co-operation & Development
(OECD).7– 9 Population factors, access to primary care, and the
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quality of primary care services may all affect HF admission rates, but
there is little previous research on these associations.
This study aimed to investigate trends in overall HF admissions in
England over a 7 year period between 2004–5 and 2010–11. It
also examines associations between HF admissions and population
factors [deprivation, race, smoking and coronary heart disease
(CHD) prevalence]; primary healthcare factors [resourcing, includ-
ing practice size and general practitioner (GP) supply, and access]
and quality of primary care, using indicators from the Quality and
Outcomes Framework (QOF), the UK pay-for-performance pro-
gramme for general practice.10
Methods
Study design
This was a national observational study of the English population regis-
tered with GP practices over a 7 year period (2004–5 to 2010–11).
Data sources
Hospital Episodes Statistics
The Hospital Episode Statistics (HES) database contains hospital admis-
sion data from all National Health Service- (NHS) funded hospitals in
England. Admissions are coded using the World Health Organization
International Classification of Diseases 10th revision (ICD-10.) ICD-10
codes for HF as a primary diagnosis included in the analysis are listed in
Table 1, in line with the US, UK, and OECD PCSC definitions. This
enabled us to explore HF as the main reason for admission, rather than
overall HF disease burden in the population. We calculated HF admission
data at general practice level for each year of the study to create an
observed admissions count for each practice. PCSC data are regularly
produced as overall rates to illustrate the overall burden of a disease
on health services, so we did not separate first and subsequent admis-
sions.
Populations
Annual age/sex breakdowns of practice populations obtained from the
NHS Information Centre were used to produce indirectly standardized
expected rates and counts for HF admissions in each practice. Practices
with , 500 registered patients (109 of 8405) were excluded from ana-
lysis as these were more likely to serve atypical patient populations or
to deliver non-standard primary care services. Ethnic breakdowns of
HES data were used to produce proportions of patients within each
ethnic group in each general practice to enable us to adjust for this in
our analysis. This assumes that coding of ethnicity within HES data is rep-
resentative of practice populations, a previously externally validated
method.11 We used the Index of Multiple Deprivation (IMD) to adjust
for deprivation.12 Resident-based IMD scores for 2004, 2007, and 2010
for each Lower Level Super Output Area (LLSOA) were converted to
practice-registered population scores using a practice/LLSOA lookup
table. We produced smoking prevalence estimates by practice from
Office for National Statistics Integrated Household Survey data.
Quality and Outcomes Framework and Patient
Experience data
The sum of the practice list sizes for the practices included in the QOF
represents . 99% of registered patients in England. Practices score
QOF points based on achievement against multiple indicators within
four domains. QOF aims to incentivize and reward good practice, and
results are published annually. We used 5 years (2006–7 to 2010–11)
of practice-level QOF data from the NHS Information Centre. We
used QOF HF prevalence data (from which clinical indicator denomina-
tors are drawn) to adjust for HF prevalence.
Particular clinical indicators within QOF change over time, and the
2010–11 HF QOF indicators are displayed in Table 2. These are in ac-
cordance with UK guidelines released by the National Institute for
Health and Clinical Excellence (NICE).13 The indicators HF1 and HF2
concern record keeping and initial diagnosis, which are less relevant to
ongoing management of HF. However we show data for HF2 as an aid
to interpreting HF prevalence data. HF4 has only been included in
QOF since 2010–11, so fewer datawere available for analysis. We there-
fore used the HF3 indicator, the percentage of patients with a current
diagnosis of HF due to LV dysfunction (LVD) who are currently treated
with an ACE inhibitor or an ARB who can tolerate therapy and for
whom there is no contraindication, as a marker of how well practices
manage HF.
To measure access to primary care from patients’ perspective, which
may be important in preventing emergency admissions from exacerba-
tions, we used indicators PE07, experience of being able to access a GP
consultation within 2 days, and PE08, ability to book an appointment
. 2 days ahead, from QOF.
Primary healthcare supply
We obtained data on GP full-time equivalents (FTEs) per 100 000 prac-
tice patient population and total practice populations (list size) from the
NHS Information Centre.
Statistical analysis
Negativebinomial regressionanalysiswasperformed rather than Poisson
regression due to overdispersion of the data. This produced incidence
rate ratios (IRRs) which in this case are admission rate ratios. Bivariate
analysis was performed initially, followed by multivariate analysis. Covari-
ates were selected using backwards stepwise selection, and non-
significant factors were removed using likelihood ratio tests. Due to
lack of independence, the clustering effect of GP practice was adjusted
Table 1 Classification of Diseases 10th revision heart failure diagnostic categories as used in primary care-sensitive
condition definitions
ICD-10 4 character codes I11.0 Hypertensive heart disease with (congestive) heart failure
I13.0 Hypertensive heart and renal disease with (congestive) heart failure
I13.2 Hypertensive heart and renal disease with both (congestive) heart failure and renal failure
150.0 Congestive heart failure
150.1 Left ventricular failure
150.9 Heart failure, unspecified
J81X Pulmonary oedema
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for in the model. Because we used robust standard errors, which are
forced by the use of cluster, the standard Wald test was used to evaluate
the model goodness-of-fit. StataTM version 11 was used for all statistical
analysis.
Ethical approval
This study was a secondary analysis of national data and thereforewasnot
submitted for ethics approval. We had approval from the NHS Informa-
tion Centre to use HES data for research.
Results
There were a total of 327 756 admissions due to HF over the 7-year
study period from 8405 GP practices. Characteristics of practice
populations are shown in Table 3. Of note, absolute achievement
on the QOF HF3 indicator (number of patients with HF on an ACE
inhibitor or ARB) was high, with a median of 90.7% [interquartile
range (IQR) 86–100%].
During the study period, average HF admissions per 100 000
patient population fell significantly by 27.3% (P, 0.001, paired
t-test used to assess significance), from 6.96/100 000 in 2004 to
5.06/100 000 in 2010. In contrast, expected HF admissions, based
on changes in population demography over the study period,
increased by 13% (P, 0.001), from 5.31/100 000 in 2004 to 6.00/
100 000 in 2010 (see Figure 1).
The practice-reported prevalence of HF fell by 7.79% (P, 0.001)
over the study period, from 0.77/100 000 in 2006 to 0.71/100 000 in
2010. There were also significant changes over time in other key cov-
ariates, including markers ofprimary care quality (seeTable4).Consid-
ering QOF achievement, achievement of HF2 (percentage of patients
with a diagnosis of HF which has been confirmed by echocardiogram
or specialist assessment) fell slightly from 97.3% in 2006–7 to
93.8% in 2010–11. There was a small but significant increase of
0.72% (P, 0.001) in achievement on the PE08 indicator (percentage
of patients who were able to book an appointment with their GP. 2
days ahead). However, there was a fall in QOF achievement for the
HF3 indicator (number of patients with HF on an ACE inhibitor or
ARB) and the PE07 indicator (percentage of patients who indicate
that they were able to obtain a consultation with their GP).
Table 5 shows the total number of observations analysed for each
covariate. Where data were not available for each year, data for the
closest available year were used as a surrogate. The total number of
unique observations foreachcovariate is shown in parentheses.Table
5 also shows the results of the bivariate clustered binomial multivari-
ate regression analysis. All covariates retained significance following
bivariate analysis; therefore, all were included in the initial multivari-
ate model.
Table 6 shows the results of the multivariate clustered negative bi-
nomial regression analysis. The covariate practice list size was
dropped from the model in this process as non-significant.
Increasing deprivation score and practice HF prevalence are asso-
ciated with increased risk of admission. Conversely, GP supply is
associated with a reduced risk of admission. However, whilst these
effect sizes are significant, they are generally small. Effect sizes are
shown as IRRs (in this context, admission risk ratios) and, for
example, HF prevalence carries an IRR of 1.07 which represents a
7.2% increase in the admission rate for every percentage point in-
crease in HF prevalence. Of note, the IRRs for markers of primary
care supply and quality were particularly small; the IRR for GP
supply was 0.991 (i.e. 0.9% reduction in admission rate for each
extra GP FTE/100 000 population) and the IRR for PE07 and PE08
QOF indicators was 0.998 (i.e. 0.2% reduction in admission rate for
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Table 2 Relevant quality and outcomes framework indicators
Heart failure indicators Points Payment
thresholdsa
Prevalence
HF prevalence per 100 practice population N/A N/A
Records
HF1: the practice can produce a register of patients with heart failure 4
Initial diagnosis
HF2: the percentage of patients with a diagnosis of heart failure (diagnosed after 1 April 2006) which has been confirmed by an
echocardiogram or by specialist assessment
6 50–90%
Ongoing management
HF3: the percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE
inhibitor or an ARB who can tolerate therapy for whom there is no contraindication.
10 45–80%
HF4: the percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE
inhibitor or ARB who are additionally treated with a beta-blocker licensed for heart failure or recorded as intolerant to or
having a contraindication to beta-blockers.
9 40–65%
Patient experience indicators
PE07 Patient experience of access (i): percentage of patients who, in the national survery, indicate that they were able to obtain a
consultation with their GP
23.5 70–90%
PE08 Patient experience of access (2): percentage of patients who, in the national survery, indicate that they were able to book an
appointment with their GP .2 days ahead
35 60–90%
GP, general practitioner, LVD, left ventricular dysfunction.
aWhere there are two values, these represent the upper and lower achievement levels required to receive the minimum and maximum payment.
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every percentage increase in score on the QOF patient experience
indicators). QOF attainment on the HF3 indicator did not significant-
ly affect admission risk, nor did smoking prevalence.
By far the largest effect size on admission risk is seen by year. Year
shows strong evidence of progressive protection against admission,
with the IRR falling sharply over time. There was a 35% admission
risk reduction between 2004 and 2010 (IRR difference 0.650, P,
0.0001). This effect retained significance despite adjusting for all the
other covariates included in our model, including all our markers of
primary care quality, and the effect size changed little after 2006.
Discussion
We found a significant reduction (27.3%) in total HF admissions over
the study period, after adjustment for population factors. This was
despite a 13% increase in the expected number of HF admissions
based on changes in population demography (see Figure 1). This re-
duction in HF admissions is in contrast to some previous studies
which have shown increasing hospitalization rates for HF over
time.14 On the other hand, other English and Scottish studies have
reported an admission peak in 1993–94,15,16 a recent American
study reported a 29.5% reduction in total HF admission rates from
1998 to 2007,17 and a Canadian study18 also reported a 27.2% reduc-
tion from 1994 to 2004. Several studies have also found reductions in
the rates of first HF admissions,4 ,19,20 although this was not always
accompanied by a reduction in overall admissions. As our main
focus was on the burden of HF admissions on health services, we
did not discriminate between first time and recurrent admissions.
We also report a reduction in HF prevalence of 7.79% between
2004 and 2010. Despite a lack of accurate data for HF prevalence,21
the majorityof previous studieshave suggested that the prevalence of
HF is increasing,22 possibly because of population ageing, increased
diagnosis of HF, and improvements in treatment and survival from is-
chaemic heart disease (IHD). However, more recent studies have
showna slowing of the rate of increase of HF prevalence in developed
countries as the incidence and mortality of HF stabilize.23,24 The
quality of diagnosis has changed little, with the percentage of patients
with a diagnosis of HF confirmed by echocardiogram or specialist as-
sessment at 97.3% in 2006–7 and 95.5% in 2010–11; therefore, the
fall cannot be explained by patients with incorrect diagnoses being
removed. However, even if the prevalence of HF in England is
falling, the effect of HF prevalence on admission risk was small and
could not fully explain the corresponding fall in HF admissions seen
over the study period.
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Table 3 Characteristics of practice populations and years from which data were analysed
Mean Median IQR Range Year(s)a
Observed HF admissions/100 000 population 5.66 4 1–8 0–56 2004–2010
Expected (indirectly standardized) HF admissions/100 000 populationb 5.66 5.55 2.38–7.96 0.02–42.83 2004–2010
Population covariates
Heart failure prevalence 0.742% 0.7% 0.42–0.92% 0–21.4% 2006–2010
CHD prevalence 5.71% 5.72% 4.72–6.68% 0–14.74% 2010
Smoking prevalence 21.00% 20.96% 16.42–25.77% 0–51.21% 2010
IMD weightingc 23.52 21.37 12.43–31.56 2.49–68.97 2004, 2007, 2010
White population (%) 71.09% 77.15% 64.07–84.72% 0.31–100% 2010
Asian population (%) 6.57% 1.27% 0.33–5.40% 0–93.03% 2010
Other population (%) 1.94% 0.73% 0.32–2.26% 0–39.51% 2010
Mixed population (%) 1.00% 0.56% 0.24–1.36% 0–27.71% 2010
Ethnicity data missing (%) 15.68% 13.78% 9.99–19.31% 0–93.90% 2010
Primary care covariates
QOF HF indicator attainment (HF2)d 95.5% 100% 93.8–100% 0–100% 2006–2010
QOF HF indicator attainment (HF3)e 90.22% 91.36% 87.64–95.54% 0–100% 2006–2010
PE07 attainmentf 82.75% 85.39% 77.25–91.79% 0–100% 2008–2010
PE08 attainmentg 75.68% 78.57% 65.96–88.57% 0–100% 2008–2010
GP FTEs/100 000 patient population 3.55 3 1.72–4.92 0.315–21.88 2004–2010
List size 6488.91 5673 3294–8892 501–40 228 2004–2010
CHD, coronary heart disease; FTE, full-time equivalent; GP, general practitioner; HF, heart failure; IMD, Index of Multiple Deprivation; IQR interquartile range; QOF, Quality
and Outcomes Framework.
aYears from which data were available for analysis.
bAdmissions are adjusted for age and sex (indirectly standardized), calculated as [standardized admission ratio (observed admission counts/expected admission counts)] × [national
admission rate/100 000].
cWeighting for each practice produced by aggregating IMD scores from postcodes of individual registered patients.
dHF2: percentage of patients with a diagnosis of HF which has been confirmed by echocardiogram or specialist assessment (since 2006–7).
eHF3: percentage of patients with a current diagnosis of HF due to LV dysfunction who are currently treated with an ACE inhibitor or ARB, who can tolerate therapy, and for whom
there is no contraindication.
fPE07: percentage of patients who, in the national survey, indicate that they were able to obtain a consultation with their GP.
gPE08: percentage of patients who, in the national survey, indicate that they were able to book an appointment with their GP .2 days ahead.
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This is the first study to go on to explore the reasons behind time
trends in HFadmission rates, and access to primary careor the quality
of primary care services. Time was progressively protective against
admission and had a much larger effect on admission risk than
other variables; therefore, the observed fall in HF admissions over
time cannot be explained completely by other covariates we consid-
ered in our model, including a range of markers of primary care
quality. This suggests that the potential for significant further reduc-
tions in emergency HF admissions by improving the clinical quality of
primary care, as currently measured, may be quite limited.
The QOF attainment on the HF3 indicator did not significantly
affect admission rates. This finding is surprising, as ACE inhibitors/
ARBs are indicated as first-line HF treatment and have been shown
conclusively to reduce mortality and hospitalizations for HF in
Figure 1 Average heart failure (HF) admission rate/100 000 population compared with the predicted HF admission rate, 2004–5 to 2010–11.
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Table 4 Change in key variables between 2004 and 2010
2004a 2010b % change P-valuec
Mean IQR Mean IQR
Observed admissions/100 000 population 6.96 3–10 5.06 1–8 –27.30 ,0.001
Expected admissions/100 000 populationd 5.31 2.31–7.43 6.00 2.46–8.50 12.99 ,0.001
Covariates
Heart failure prevalence 0.77 0.51–0.97 0.71 0.50–0.90 –7.79 ,0.001
QOF HF indicator attainment (HF3)e 91.19 86–100 90.68 86–100 –1.41 0.029
PE07 attainmentf 83.94 79.29–92.98 82.18 76.42–91.00 –2.10 ,0.001
PE08 attainmentg 74.80 64.89–87.61 75.34 66.03–87.50 0.72 ,0.001
GP FTEs/100 000 pateint population 3.31 1.6–4.6 3.76 2–5 13.6 ,0.001
List size 6248.57 3141–8540 6697.58 2239–9197 7.19 ,0.001
IMD weighting 23.84 13.36–32.43 23.75 13.63–32.25 –0.38 0.504
FTE, full-time equivalent; GP, general practitioner; HF, heart failure; IMD, Index of Multiple Deprivation; IQR interquartile range; QOF, Quality and Outcomes Framework.
a2004 or first year for which unique data were available for analysis.
b2010 or last year for which unique data werr available for analysis.
cPaired t-test for differences between means.
dAdmissions are adjusted for age and sex (indirectly standardized), calculated as [standardized admission ratio (observed admission counts/expected admission counts)] × [national
admission rate/100 000].
eHF3: percentage of patients with a current diagnosis of heart failure due to LV dysfunction who are currently treated with an ACE inhibitor or ARB, who can tolerate therapy, and for
whom there is no contraindication.
fPE07: percentage of patients who, in the national survey, indicate that they were able to obtain a consultation with their GP.
gPE08: percentage of patients who, in the national survey, indicate that they were able to book an appointment with their GP .2 days ahead.
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major clinical trials.25 This finding may be explained by the fact that
overall scores on the HF3 indicator were generally high throughout
the study period, and this ‘ceiling effect’ of QOF achievement may
have limited its effectiveness as a discriminator between practices.
Practices can also exclude a small proportion of cases from QOF indi-
cators. If the proportion of excluded patients had greatly decreased,
and they are now receiving treatment, this could explain some de-
crease in admissions. However, this proportion has remained
steady at 8.1% between 2005–6 and 2010–11. Furthermore, the
HF3 QOF indicator does not consider what dose of medication
the patients are taking, nor their compliance with prescribed medica-
tion. There may be significant variation between the willingness of
practices to up-titrate medication to the maximum tolerated dose
and to ensure maximum patient concordance, which this analysis
was unable to measure.
The HF3 indicator only includes patients with LVD, despite the fact
the HF admission totals included both patients with LVD and those
with preserved LVEF. Increased use of evidence-based medications
may only be expected to have a limited effect in the group with pre-
served LVEF, and this could at least partly explain why scores on the
HF3 indicator were not seen to have a significant effect on admission
rates. The non-significance of the HF3 indicator scores may also be
related to the ICD-10 code J81X (pulmonary oedema) included as
an indicatorof an admission for HF. This codewas included in the ana-
lysis in line with PCSC definitions.7,9 However, other non-HF diagno-
ses are potentially included in this diagnostic code (e.g. fluid overload
in a dialysis patient). There are few data available regarding the sensi-
tivity or specificity of this code as an indicator of HF.
HF3 was considered the best measurement of ongoing manage-
ment of HF, and therefore most relevant to HF as a PCSC. HF2,
the percentage of patients with a diagnosis of HF which has been con-
firmed by echocardiogram or specialist assessment, may provide a
marker of the quality of HF diagnosis, but achievement has been
very high—greater than 95%—throughout the period studied. Simi-
larly, HF4, the percentage of patients who are additionally treated
with a beta-blocker, may provide a more sensitivemarkerof the prac-
tice pharmacological management of HF. Beta-blocker uptake has
increased in the English population over the study period,23 and
this could at least partially explain the fall in admission rates. Both
these alternative OQF HF indicators could be investigated further
in future studies.
We did not include other QOF clinical domain indicators in our
analysis, e.g. for IHD, hypertension, diabetes, or smoking, nor did
we look at time trends in IHD or smoking prevalence over the
study period. However, smoking prevalence was not significantly
associated with HF admissions, and IHD prevalence was only asso-
ciated with a small reduction in admission risk overall, so it is unlikely
that these factors could account for the total reduction in admission
risk with time. Nonetheless, further investigation of these indicators
may be warranted.
Higheruseof IHDand hypertension secondaryprevention therap-
ies may also contribute to the as yet unexplained reduction in HF ad-
mission risk over time. Other pharmacological therapies have also
been shown to reduce the risk of admission in HF (as well as HF mor-
tality and other markers of morbidity). These include beta-blockers,
aldosterone antagonists, and statins.26 Other evidence-based, non-
pharmacological strategies are likely to have played a role in reducing
admission rates, including specialist HF clinics,27 CRT,28 specialized
multidisciplinary follow-up,29 exercise-based rehabilitation,30 tele-
medicine,31 specialist nurses,32 and self-management programmes.33
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Table 5 Bivariate clustered negative binomial regression analysis for heart failure admissions
No. of observationsa IRR P-value 95% CI
Deprivation 56 318 (24 140) 1.017 ,0.001 1.016–1.018
Heart failure prevalence 57,811 1.026 0.008 1.007–1.045
CHD prevalence 55,394 1.008 0.001 1.003–1.013
Smoking prevalence 56,263 1.013 ,0.001 1.012–1.014
QOF attainment (HF3)b 57 022 (40 735) 1.001 0.041 1.000–1.002
PE07 attainmentc 56 472 (24 208) 0.994 ,0.001 0.994–0.995
PE08 attainmentd 56 044 (24 170) 0.995 ,0.001 0.995–0.996
GP supply (FTEs) 57 139 (49 188) 0.963 ,0.001 0.961–0.966
Practice list size 57 902 1.000 ,0.001 1.000–1.000
2005 (vs. 2004) 57 902 0.952 ,0.001 0.929–0.976
2006 (vs. 2004) 0.839 ,0.001 0.818–0.860
2007 (vs. 2004) 0.649 ,0.001 0.633–0.666
2008 (vs. 2004) 0.659 ,0.001 0.642–0.676
2009 (vs. 2004) 0.648 ,0.001 0.631–0.664
2010 (vs. 2004) 0.647 ,0.001 0.631–0.664
CHD, coronary heart disease; CI, confidence interval; FTE, full-time equivalent; GP, general practitioner; HR, hazard ratio; IRR, incidence rate rato; QOF, Quality and Outcomes
Framework.
aWhere data were not available for each year, data for the closest available year were used as a surrogate. The total number of unique observations is shown in parentheses.
bQOF attainment (HF3): percentage of patients with a current diagnosis of heart failure due to LV dysfunction who are currently treated with an ACE inhibitor or ARB, who can
tolerate therapy, and for whom there is no contraindication.
cPE07 attainment: percentage of patients who, in the national patient survey, indicate that they were able to obtain a consultation with their GP.
dPE08 attainment: percentage of patients who, in the national survey, indicate that they were able to book an appointment with their GP .2 days ahead.
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Other possible reasons to explain the reduction in HF admissions
over time could include a general shift away from inpatient care, with
limited inpatient bed resources, targets for the reduction of costly
hospital admissions, and greater emphasis on community care, in-
cluding use of risk stratification (e.g. using BNP measurement),
rapid follow-up, and more hospital to community HF nursing
teams. It is difficult to obtain any national data on these fairly new ser-
vices, and we were not able to include in the analysis the availability of
community care, or markers of access to secondary care. These may
warrant further investigation.
Patient perceptions of access to GPs could affect the admission
rate by resulting in patients being more likely to attend hospital Acci-
dent & Emergency departments and hence be admitted. Patient-
reported access to GPs (as measured via the PE07 and PE08 QOF
indicators) had a small but significant effect on the risk of admission.
Access to community HF teams and rapid follow-up have been
shown in randomized controlled trials to reduce the risk of readmis-
sion significantly, and may well have a much larger effect on reducing
admission risk than access to GPs alone. The fact that the QOF HF3
score was not associated with HF admission risk is not likely to be due
to reporting bias, as QOF data are extracted directly from patients’
electronic health records, which are used for clinical care. Other
factors, including unmeasured patient characteristics, or a practice’s
ability to ‘game’ the system, have been proposed as reasons why
measurements such as QOF may not accurately reflect the quality
of clinical care given or received. Conversely, effective, holistic man-
agement of HF patients by high quality primary care teams could
reduce admissions by influencing medication compliance, self-care,
symptom recognition, and consulting behaviour. This is not mea-
sured by QOF indicators.
Heart failure is a condition associated with many co-morbidities,
and so patients may benefit from having their other diseases con-
trolled. For example, depression is prevalent amongst HF patients
and is associated with an increased risk of mortality and hospital ad-
mission,34 and we did not assess whether primary care was more ef-
fectively addressing co-morbid depression. Likewise, appointment
availability (as measured by the PE07 and PE08 QOF indicators) is
just one aspect of patients’ consulting behaviour. The more
nuanced aspects of primary care quality are undoubtedly harder to
measure, but may be considerably more sensitive.
Limitations
This analysis included only admissions where HF was coded as the
primary reason for admission, although trends for readmissions for
HF are also important, especially with a multimorbid, ageing popula-
tion. Previous reports have suggested that HF readmission rates can
be significantly decreased via specific HF-targeted interventions, and
it is possible that the fall in admission risk is largely explained by a re-
duction in the riskof recurrent admissions in high risk individuals. Fur-
thermore, this approach may have missed some cases where HF may
have been an underlying reason for admission but not the primary
reason.
Most of the IRRs are close to unity, suggesting a small clinical effect.
However considered as a percentage reduction in risk admission,
they may in fact be clinically relevant. For example, PE08 has an IRR
of 0.998, which means there is a 0.2% reduction in admission rate
for every 1% increase in score on the QOF indicator PE08. That
means that if a practice scores10%higheron thePE08QOF indicator,
its admission rate is likely to be 2% lower. Given that the IQR for this
particular indicator is .20%, this particular indicator alone could
result in a .4% difference in admission risk between practices
scoring in the topquartercomparedwith the bottomquarterofprac-
tices. Further exploration using individually linked data may be useful
in informing future strategies to reduce admission rates further.35
Examining trends in the average duration of inpatient stay would iden-
tify whether the fall in total admission has been accompanied by a fall
in duration of stay, as reported elsewhere.15
Conclusions
This study has shown that HF admissions in England are decreasing
over time. Deprivation and high practice HF prevalence increase
the risk of admission for HF, whereas greater GP supply and better
access to GPs reduce risk of admission. However, despite statistical
significance, these effects are small in clinical terms. Coverage of pre-
scribing of an ACE inhibitor or an ARB does not affect the risk of ad-
mission.Overall, year hasby far the strongest protectiveeffect against
admission, with a steady reduction in admission risk from 2004 to
2010. This reduction cannot be explained by available national
markers of primary care quality or access to primary care, and this
study does not provide any support for the hypothesis that in the
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Table 6 Multivariate clustered negative binomial
regression analysis for heart failure admissions
IRR P-value 95% CI
Deprivation 1.014367 ,0.001 1.013–1.016
Heart failure prevalence 1.072211 ,0.001 1.049–1.096
CHD prevalence 0.975838 ,0.001 0.967–0.985
Smoking prevalence 1.000494 0.593 0.999–1.002
QOF attainment (HF3)a 0.999751 0.625 0.999–1.001
PE07 attainmentb 0.998424 ,0.001 0.998–0.999
PE08 attainmentc 0.998182 ,0.001 0.998–0.999
GP supply (FTEs) 0.99092 ,0.001 0.986–0.996
Practice list size Dropped
2005 (vs. 2004) 0.950908 ,0.001 0.937–0.965
2006 (vs. 2004) 0.831556 ,0.001 0.818–0.846
2007 (vs. 2004) 0.646906 ,0.001 0.634–0.661
2008 (vs. 2004) 0.664165 ,0.001 0.650–0.678
2009 (vs. 2004) 0.651721 ,0.001 0.638–0.665
2010 (vs. 2004) 0.650321 ,0.001 0.637–0.664
CHD, coronary heart disease; CI, confidence interval; FTE, full-time equivalent; GP,
general practitioner; IRR, incidence rate rato; QOF, Quality and Outcomes
Framework.
Wald x2(14) ¼ 5284.74.
Log pseudolikelihood ¼ –140815.22.
Probability . x2 ¼ , 0.001.
aQOF attainment (HF3): percentage of patients with a current diagnosis of heart
failure due to LV dysfunction who are currently treated with an ACE inhibitor or
ARB, who can tolerate therapy, and for whom there is no contraindication.
bPE07 attainment: percentage of patients who, in the national patient survey, indicate
that they were able to obtain a consultation with their GP.
cPE08 attainment: percentage of patients who, in the national survey, indicate that
they were able to book an appointment with their GP .2 days ahead.
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UK HF admissions are sensitive to primary care quality, as currently
measured. The reduction may be due to the development of non-
pharmacological interventions about which there is a lack of national
data, or the more nuanced aspects of primary care quality not mea-
sured by QOF. Further work is required to identify the reasons
behind the reduction in admissions, for example by longitudinal
patient-level analysis of electronic health records, supplemented
with local surveys of new HF services, or data from the Heart
Failure National Clinical Audit.36 This may enable us to identify
which initiatives are having a greater impact on admission rates and
provide further evidence for improving HF services.
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